Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review
Shoshana Revel‐Vilk, Maria Fuller, Ari Zimran
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 19, pp. 7159-7159
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here?
Neal J. Weinreb, Özlem Göker-Alpan, Priya S. Kishnani, et al.
Molecular Genetics and Metabolism (2022) Vol. 136, Iss. 1, pp. 4-21
Open Access | Times Cited: 44
Challenges in Gaucher disease: Perspectives from an expert panel
Gregory A. Grabowski, Priya S. Kishnani, Roy N. Alcalay, et al.
Molecular Genetics and Metabolism (2025), pp. 109074-109074
Closed Access | Times Cited: 1
Gaucher disease – more than just a rare lipid storage disease
Jaehyeok Roh, Subbaya Subramanian, Neal J. Weinreb, et al.
Journal of Molecular Medicine (2022) Vol. 100, Iss. 4, pp. 499-518
Closed Access | Times Cited: 32
Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1
Andrea Dardis, Helen Michelakakis, Paula Rozenfeld, et al.
Orphanet Journal of Rare Diseases (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 30
Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review
Gaetano Giuffrida, Uroš Markovic, Annalisa Condorelli, et al.
Orphanet Journal of Rare Diseases (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 21
Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?
Tama Dinur, Peter Bauer, Christian Beetz, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1627-1627
Open Access | Times Cited: 25
Newborn Screening for Fabry Disease: Current Status of Knowledge
Vincenza Gragnaniello, Alessandro P. Burlina, Anna Commone, et al.
International Journal of Neonatal Screening (2023) Vol. 9, Iss. 2, pp. 31-31
Open Access | Times Cited: 15
Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity
Daniel Ysselstein, Tiffany Young, Maria Nguyen, et al.
Movement Disorders (2021) Vol. 36, Iss. 12, pp. 2719-2730
Open Access | Times Cited: 31
Use of Ambroxol as Therapy for Gaucher Disease
Xia Zhan, Huiwen Zhang, Gustavo Maegawa, et al.
JAMA Network Open (2023) Vol. 6, Iss. 6, pp. e2319364-e2319364
Open Access | Times Cited: 12
Lipidomics—Paving the Road towards Better Insight and Precision Medicine in Rare Metabolic Diseases
Martina Zandl‐Lang, Barbara Plecko, Harald Köfeler
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1709-1709
Open Access | Times Cited: 11
High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy
Majdolen Istaiti, Dafna Frydman, Tama Dinur, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6732-6732
Open Access | Times Cited: 11
Natural history of inflammation and impaired autophagy in children with Gaucher disease identified by newborn screening
Vincenza Gragnaniello, Daniela Gueraldi, Alessandro Saracini, et al.
Molecular Genetics and Metabolism Reports (2025) Vol. 42, pp. 101187-101187
Closed Access
Evaluation of Lyso-Gb1 as a biomarker for Gaucher disease treatment outcomes using data from the Gaucher Outcome Survey
Ari Zimran, Shoshana Revel‐Vilk, Tama Dinur, et al.
Orphanet Journal of Rare Diseases (2025) Vol. 20, Iss. 1
Open Access
Newborn Screening for Gaucher Disease: The New Jersey Experience
Caitlin Menello, Shaney Pressley, Madeline Steffensen, et al.
International Journal of Neonatal Screening (2025) Vol. 11, Iss. 2, pp. 34-34
Open Access
Exploration of Bone Alterations in Gaucher Disease Type 1: A Global and Systematic Analysis of Scientific Knowledge
Daniela Arturo-Terranova, Lina Johanna Moreno Giraldo, José Soto
Journal of Inborn Errors of Metabolism and Screening (2025) Vol. 13
Open Access
Current and emerging pharmacotherapy for Gaucher disease in pediatric populations
Richard Sam, Emory Ryan, Emily Daykin, et al.
Expert Opinion on Pharmacotherapy (2021) Vol. 22, Iss. 11, pp. 1489-1503
Open Access | Times Cited: 25
Plasma neurofilament light, glial fibrillary acidic protein and lysosphingolipid biomarkers for pharmacodynamics and disease monitoring of GM2 and GM1 gangliosidoses patients
Richard W.D. Welford, Hervé Farine, Michel A. Steiner, et al.
Molecular Genetics and Metabolism Reports (2022) Vol. 30, pp. 100843-100843
Open Access | Times Cited: 18
Neuronopathic Gaucher disease: Beyond lysosomal dysfunction
Nohela B. Arévalo, Cristian M. Lamaizon, Viviana A. Cavieres, et al.
Frontiers in Molecular Neuroscience (2022) Vol. 15
Open Access | Times Cited: 17
Neuronopathic Gaucher disease: Rare in the West, common in the East
Özlem Göker-Alpan, Margarita M. Ivanova
Journal of Inherited Metabolic Disease (2024) Vol. 47, Iss. 5, pp. 917-934
Open Access | Times Cited: 3
Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: Results from a Delphi consensus
Priya S. Kishnani, Walla Al‐Hertani, Manisha Balwani, et al.
Molecular Genetics and Metabolism (2021) Vol. 135, Iss. 2, pp. 154-162
Open Access | Times Cited: 23
Therapeutic Uses of Bacterial Subunit Toxins
Clifford A. Lingwood
Toxins (2021) Vol. 13, Iss. 6, pp. 378-378
Open Access | Times Cited: 22
Hematological manifestations and complications of Gaucher disease
Shoshana Revel‐Vilk, Jeff Szer, Ari Zimran
Expert Review of Hematology (2021) Vol. 14, Iss. 4, pp. 347-354
Closed Access | Times Cited: 21
Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic Formulations
Tama Dinur, Ulrike Grittner, Shoshana Revel‐Vilk, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 14, pp. 7699-7699
Open Access | Times Cited: 18
Detecting lysosomal storage disorders by glycomic profiling using liquid chromatography mass spectrometry
Justin Mak, Tina M. Cowan
Molecular Genetics and Metabolism (2021) Vol. 134, Iss. 1-2, pp. 43-52
Open Access | Times Cited: 17
A new brain‐penetrant glucosylceramide synthase inhibitor as potential Therapeutics for Gaucher disease
Takahiro Fujii, Yuta Tanaka, Hideyuki Oki, et al.
Journal of Neurochemistry (2021) Vol. 159, Iss. 3, pp. 543-553
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top